Instil Bio, Inc. (TIL) stock
Close on Nov 13, 2026Market cap $41.23MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $41.23M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.38
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$30.28M
- EPS, diluted
- -$4.47
- Book value per share
- $15.83
- Diluted shares
- 7M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $6.24
- Open
- $6.20
- Day's range
- $6.02 – $6.50
- Volume
- 51,629
- Average volume (20 days)
- 72,962
- Beta (5 years)
- 2.87
- 52-week range
- $5.56 – $15.23
- RSI (14 days)
- 40.8
- Volatility (1 year)
- 66.9%
- Relative volume
- 1.93×
- WACC
- 17.6%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | TIL | S&P 500 | Difference | TIL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.6% | -3.0% | +1.4 pts | ||
| 3 months | -16.4% | -2.8% | −13.6 pts | ||
| Year to date | -44.7% | +11.5% | −56.2 pts | ||
| 1 year | -56.3% | +13.5% | −69.8 pts | ||
| 3 years | -15.6% | +77.7% | −93.3 pts | -5.5% | +21.1% |
| 5 years | -98.5% | +72.6% | −171.1 pts | -57.0% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Instil Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Instil Bio
Biological Products, (No Diagnostic Substances)
The company is a biotechnology enterprise focused on discovering, acquiring, and advancing innovative therapeutic candidates for conditions with significant unmet medical need. Its core operational strategy revolves around pursuing acquisitions and in-licensing opportunities for novel drug candidates rather than selling established commercial products. Historically, its research activities included cell therapies, specifically a proprietary folate receptor alpha co-stimulatory antigen receptor tumor-infiltrating lymphocyte therapy for cancer, alongside an in-licensed bispecific antibody candidate, AXN-2510, targeting solid tumor cancers. Because the enterprise operates as a clinical development entity without approved therapies, it has no commercial customer base.
Company profile, executives and historyInstil Bio stock: common questions
What is Instil Bio's stock price?
TIL closed at $6.08 on Nov 13, 2026, down 2.56% on the day. Over the past 52 weeks it traded between $5.56 and $15.23.
What is Instil Bio's market cap?
Instil Bio was worth $41.23M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is TIL's P/E ratio?
Instil Bio lost money over the twelve months to Jun 30, 2026 (diluted EPS -$4.47), so it has no meaningful P/E ratio.
Does Instil Bio pay a dividend?
No. Instil Bio has not paid a cash dividend over the last twelve months.
When does Instil Bio report earnings next?
Instil Bio's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has TIL stock performed over the past year?
Including dividends, TIL returned -56.3% over the past year, against +13.5% for the S&P 500.
Who are Instil Bio's competitors?
Companies most similar to Instil Bio by business, industry and size include CPMV, INAB, CERO, INBX, CLDI.
See a number that looks wrong?